학술논문

Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR -Mutant Non–Small-Cell Lung Cancer.
Document Type
Academic Journal
Source
Journal of Clinical Oncology (J CLIN ONCOL), 4/20/2024; 42(12): 1350-1356. (12p)
Subject
Language
English
ISSN
0732-183X